Literature DB >> 25551240

A naturalistic study of the association between antidepressant treatment and outcome of smoking cessation treatment.

Todd Zorick1, Mark A Mandelkern, Arthur L Brody.   

Abstract

OBJECTIVE: Psychiatric, medical, and substance use comorbidities are highly prevalent among smokers, and many of these comorbidities have been found to be associated with reduced rate of success in clinical trials for smoking cessation. While much has been established about the best available treatments from these clinical trials, little is known about the effect of concomitant psychiatric medications on quit rates in smoking cessation programs. On the basis of results in populations with tobacco dependence and other substance use disorders, we hypothesized that smokers taking antidepressants would have a lower rate of quitting in an outpatient smoking cessation program.
METHOD: We performed a naturalistic chart review of veterans (N = 144) enrolled in the Veterans Affairs Greater Los Angeles Mental Health Clinic Smoking Cessation Program from March 2011 through July 2013, who met DSM-IV-TR criteria for nicotine dependence. The primary outcome was smoking cessation with treatment, as evidenced by a patient report of at least 1 week of abstinence and an exhaled carbon monoxide level of ≤ 6 ppm (if available) at the end of acute treatment, with comparators including concomitant psychotropic medication treatment, psychiatric and medical comorbidities, and the presence of a substance use disorder history. We utilized stepwise binary logistic regression as the main statistical technique.
RESULTS: We found that current antidepressant treatment (P = .003) and history of substance use disorder (P = .01) (particularly cocaine [P = .02]) were associated with a lower rate of quitting smoking. Furthermore, the association between antidepressant treatment and reduced rate of smoking cessation was primarily seen in patients with a history of substance use disorder (P = .003).
CONCLUSIONS: While preliminary, these results suggest an important clinical interaction meriting future study. If these findings are confirmed, clinicians may want to consider the risk of reduced ability to quit smoking in patients with a history of substance use disorder who are taking antidepressants. © Copyright 2014 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25551240      PMCID: PMC4666295          DOI: 10.4088/JCP.14m09012

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  22 in total

Review 1.  Past major depression and smoking cessation outcome: a systematic review and meta-analysis update.

Authors:  Brian Hitsman; George D Papandonatos; Dennis E McChargue; Andrew DeMott; María José Herrera; Bonnie Spring; Belinda Borrelli; Raymond Niaura
Journal:  Addiction       Date:  2013-02       Impact factor: 6.526

2.  Predictors of success for smoking cessation at the workplace: a longitudinal study.

Authors:  Daiana Stolz; Andreas Scherr; Bruno Seiffert; Martin Kuster; Anja Meyer; Karl-Olov Fagerström; Michael Tamm
Journal:  Respiration       Date:  2013-04-10       Impact factor: 3.580

Review 3.  Treatment of tobacco dependence in people with mental health and addictive disorders.

Authors:  Kristen M Mackowick; Marie-Josee Lynch; Andrea H Weinberger; Tony P George
Journal:  Curr Psychiatry Rep       Date:  2012-10       Impact factor: 5.285

4.  A randomized controlled trial of fluoxetine in the treatment of cocaine dependence among methadone-maintained patients.

Authors:  Erin L Winstanley; George E Bigelow; Kenneth Silverman; Rolley E Johnson; Eric C Strain
Journal:  J Subst Abuse Treat       Date:  2011-01-26

5.  A double-blind, randomized trial of sertraline for alcohol dependence: moderation by age of onset [corrected] and 5-hydroxytryptamine transporter-linked promoter region genotype.

Authors:  Henry R Kranzler; Stephen Armeli; Howard Tennen; Jonathan Covault; Richard Feinn; Albert J Arias; Helen Pettinati; Cheryl Oncken
Journal:  J Clin Psychopharmacol       Date:  2011-02       Impact factor: 3.153

6.  Poor response to sertraline in methamphetamine dependence is associated with sustained craving for methamphetamine.

Authors:  Todd Zorick; Catherine A Sugar; Gerhard Hellemann; Steve Shoptaw; Edythe D London
Journal:  Drug Alcohol Depend       Date:  2011-05-17       Impact factor: 4.492

Review 7.  Combined pharmacotherapy and behavioural interventions for smoking cessation.

Authors:  Lindsay F Stead; Tim Lancaster
Journal:  Cochrane Database Syst Rev       Date:  2012-10-17

Review 8.  Smoking cessation interventions for smokers with current or past depression.

Authors:  Regina M van der Meer; Marc C Willemsen; Filip Smit; Pim Cuijpers
Journal:  Cochrane Database Syst Rev       Date:  2013-08-21

Review 9.  Tobacco use in 3 billion individuals from 16 countries: an analysis of nationally representative cross-sectional household surveys.

Authors:  Gary A Giovino; Sara A Mirza; Jonathan M Samet; Prakash C Gupta; Martin J Jarvis; Neeraj Bhala; Richard Peto; Witold Zatonski; Jason Hsia; Jeremy Morton; Krishna M Palipudi; Samira Asma
Journal:  Lancet       Date:  2012-08-18       Impact factor: 79.321

Review 10.  Rediscovering trazodone for the treatment of major depressive disorder.

Authors:  Andrea Fagiolini; Alessandro Comandini; Mario Catena Dell'Osso; Siegfried Kasper
Journal:  CNS Drugs       Date:  2012-12       Impact factor: 5.749

View more
  3 in total

1.  Combination Extended Smoking Cessation Treatment Plus Home Visits for Smokers With Schizophrenia: A Randomized Controlled Trial.

Authors:  Arthur L Brody; Todd Zorick; Robert Hubert; Gerhard S Hellemann; Shabnam Balali; Sarah S Kawasaki; Lizette Y Garcia; Ryutaro Enoki; Paul Abraham; Paulina Young; Charles McCreary
Journal:  Nicotine Tob Res       Date:  2016-08-03       Impact factor: 4.244

2.  The Effects of Citalopram and Thalamic Dopamine D2/3 Receptor Availability on Decision-Making and Loss Aversion in Alcohol Dependence.

Authors:  Todd Zorick; Kyoji Okita; K Brooke Renard; Mark A Mandelkern; Arthur L Brody; Edythe D London
Journal:  Psychiatry J       Date:  2022-09-20

3.  Success rates in smoking cessation: Psychological preparation plays a critical role and interacts with other factors such as psychoactive substances.

Authors:  Bertrand Joly; Jean Perriot; Philippe d'Athis; Emmanuel Chazard; Georges Brousse; Catherine Quantin
Journal:  PLoS One       Date:  2017-10-11       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.